SecBot

SecBot
OTC· Pharmaceutical Preparations· CIK 0000353278

NVO

NOVO NORDISK A S
$37.21 ▼ -0.50%
Prev close $37.40
Market cap$167.9B
ConsensusSell
12-mo target$45.88 (+23.3%)
▼ Bearish
Analyst conviction 3/10
High Impact Filing (7/10)34 New Institutional Positions16 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on NVO right now — valuation, ownership and activity at a glance.
Market Cap
$167.9B
Cap Size
Large Cap
Analyst Consensus
Hold (31%)
Inst. Holders
50 funds
Inst. Value
$13.5B
Inst. Activity
34 buys / 16 sells
Social Sentiment
46° Neutral
SEC Reports
20
Congressional
1 trades
Price chart 30d -20.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Event
Novo Nordisk A/S et al v. Aios Inc. et al
Court ruling (cand) — Docket: 4:25-cv-06560
Sep 22, 2026 Event
VICTOZA
Limited Availability: Estimated shortage duration: TBD (Delay in shipping of the drug) [Endocrinolog
Sep 21, 2026 clinical_trial_readout
T-90d Trial Readout: NNC0662-0419 (Phase 2)
Trial: A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living
Sep 15, 2026 SEC
Analysis based on filing metadata only — document content was unavailable. The filing is a Form 6-K submitted by Novo No
6-K — Impact 3/10
Sep 9, 2026 SEC
Novo Nordisk and defendant Aios Inc. (d/b/a Fella Health) entered a stipulated ESI discovery order in the Northern Distr
COURT-RULING — Impact 1/10
Sep 9, 2026 SEC
Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 15 billion buyback pr
6-K — Impact 2/10
Aug 26, 2026 Congress
C. Franklin buy
$1,001 - $15,000 — House
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
9,180,490 shares ($440.1M)
Analyst ratings buy % -44.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Sell 31% rate it Buy or better · 36 analysts
Strong Buy 5 14% Buy 6 17% Hold 22 61% Sell 2 6% Strong Sell 1 3%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 11, 2026Morgan StanleyDOWNGRADEUnderweight 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202656222131%
Aug 1, 202658221135%
Jul 1, 202658221135%
Jun 1, 202657231132%
May 1, 202657231132%
Apr 1, 202657231132%
Mar 1, 202658192038%
Feb 1, 2026612132153%
Price targets
Where 12 covering analysts think NVO trades over the next 12 months.
$45.88 +23.3% upside Strong Buy
Current$37.22 Low$39.25 Median$43.80 High$62.12 12 analysts
$39.25$62.12
Analyst rating Hold· 2.7/5 as of Oct 2, 2026
Social media sentiment mood +7.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
46°
Neutral
BearishNeutralBullish
30 mentions 9 bullish 12 bearish 9 neutral
Recent posts
investing Bullish 10d 5h ago
Why are people here so against investing in single stocks?
▲ 1 · 💬 7· ⚡ 0.5
wallstreetbets Bullish 10d 22h ago
NVO YOLO
▲ 1 · 💬 5· ⚡ 0.5
wallstreetbets Bearish 11d 3h ago
Finall divorced NVO
▲ 1 · 💬 6· ⚡ 0.5
wallstreetbets Neutral 25d 4h ago
$NVO (makes ozempic) just killed TWO Phase 3 trials
▲ 1 · 💬 5· ⚡ 0.5
stocks Bearish 1mo ago
Exploring the "GLP-1 aesthetics basket"
▲ 1 · 💬 6· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 1 bullish, 3 bearish, 1 mixed, 15 neutral · avg impact 2.9/10.
NEUTRAL6-K3/10
Analysis based on filing metadata only — document content was unavailable. The filing is a Form 6-K
Sep 15, 2026
NEUTRALCOURT-RULING1/10
Novo Nordisk and defendant Aios Inc. (d/b/a Fella Health) entered a stipulated ESI discovery order i
Sep 9, 2026
NEUTRAL6-K2/10
Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 1
Sep 9, 2026
NEUTRALCOURT-RULING1/10
A magistrate judge in the Novo Nordisk patent lawsuit against Mochi Health Corp. issued a procedural
Sep 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Phase Phase 2 — COMPLETED
Sep 30, 2026
Clinical Trial
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Phase Phase 3 — COMPLETED
Sep 28, 2026
Clinical Trial
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Phase Phase 3 — COMPLETED
Sep 25, 2026
Clinical Trial
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Phase Phase 3 — COMPLETED
Sep 24, 2026
Clinical Trial
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$5.00$4.68–$5.3311.2%-2.5%3↑ 0↓$73.0B4
Next Q$4.41$3.97–$5.12-27.0%-0.5%1↑ 2↓$74.2B4
Current FY$22.75$21.01–$24.53-1.2%-1.4%1↑ 0↓$300.2B8
Next FY$22.04$16.88–$23.74-3.1%+0.2%5↑ 1↓$304.1B8
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$5.005—
7d ago$5.005—
30d ago$5.133-0.128
60d ago$4.702+0.303
90d ago$4.655+0.349
Institutional ownership
Which big funds own NVO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $13.5B total value (269,401,466 shares) as of 2026-Q2. Top holders: DODGE, LOOMIS, FRANKLIN. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
DODGE & COX20,397,110$977.8M7.2%—
LOOMIS SAYLES & CO L P18,594,352$891.4M6.6%—
FRANKLIN RESOURCES INC13,041,109$625.2M4.6%—
PeakShares LLC12,642$606.1M4.5%—
SUSQUEHANNA INTERNATIONAL GROUP, LLP12,009,200$575.7M4.3%TRIM -56.6%
MORGAN STANLEY11,659,869$559.0M4.1%—
BANK OF AMERICA CORP /DE/11,176,712$535.8M4.0%—
Capital International Investors9,721,180$467.6M3.5%—
GOLDMAN SACHS GROUP INC9,180,490$440.1M3.3%ADD +79.3%
CITADEL ADVISORS LLC9,059,400$434.3M3.2%TRIM -50.1%
Recent position changes
FundActionPrevCurrentChangeValue
GOLDMAN SACHS GROUP INCADD5,121,0379,180,490+79.3%$440.1M
FRED ALGER MANAGEMENT, LLCNEW—4,907,570—$235.3M
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM11,106,1114,815,576-56.6%$230.9M
WELLS FARGO & COMPANY/MNADD3,642,5994,657,642+27.9%$223.3M
BlackRock, Inc.ADD2,951,3533,861,182+30.8%$185.1M
BANK OF NOVA SCOTIADOUBLED54,4073,065,015+5533.5%$146.9M
Nuveen, LLCNEW—2,969,256—$142.3M
FARALLON CAPITAL MANAGEMENT, L.L.C.DOUBLED782,0002,619,000+234.9%$125.6M
FMR LLCADD1,352,6202,306,393+70.5%$110.6M
MILLENNIUM MANAGEMENT LLCADD1,408,8532,035,939+44.5%$97.6M
Congressional trades
NVO trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Aug 26, 2026C. FranklinRHOUSEBUY$1,001 - $15,000Novo Nordisk A/SSep 18, 2026(24d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NVO.
Shares short
26,339,706
Settlement Sep 15, 2026
Change vs prior
-16.8%
Semi-monthly cycle
Days to cover
2.9
At avg daily volume
Of shares outstanding
≈0.6%
Estimate — not % of float
All NVO filing & press-release reports (26)